Related Experiment Video
Updated: Jun 27, 2026
Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model
Published on: October 16, 2017
Transgenic model of cardiac rhabdomyosarcoma formation
Christiane Köbbert1, Christa Möllmann, Michael Schäfers
1Department of Cardiology and Angiology, Hospital of the University of Münster, Münster, Germany.
Objectives:
Cardiac rhabdomyosarcomas are rare, and the pathogenesis of this detrimental disease is widely unknown. Most data are obtained from case reports or small series, and models for systematic pathogenetic studies are lacking. We aimed to establish a transgenic mouse model of cardiac rhabdomyosarcoma formation.
Methods:
Standard techniques were used to construct a minigene comprised of the 5' region of the 1.4-kb SM22alpha gene (expressed in embryonic cardiac muscle) and the 2.7-kb SV40 T antigen early region. This T antigen fragment includes the coding sequences for the binding sites of p53 and the proteins of the pRb family. Genotyping of transgenic mice was performed by means of polymerase chain reaction, and phenotypic expression was evaluated by means of immunohistochemistry.
Results:
Transgenic mice were studied at the age of approximately 8 to 12 weeks. Cardiac tumors were found of variable size in the left or right sides of the heart and were associated with T antigen expression. Histologic analysis revealed a 3.1-fold enhanced cell density, enlarged cell nuclei, and a 3.4-fold enhanced DNA content. Phenotypic characterization of cardiac tumors resulted in positive staining for desmin, smooth muscle alpha-actin, troponin C, and Myo D1, which met the criteria for rhabdomyosarcomas.
Conclusions:
To the best of our knowledge, the present study is the first description of a mouse model of cardiac rhabdomyosarcoma formation based on genetic modulation. Our model will be a valuable tool for illuminating the pathogenesis of cardiac rhabdomyosarcomas and will allow the testing of new therapeutic approaches to fight this dreadful disease.
Insights
Researchers developed a novel transgenic mouse model for studying cardiac rhabdomyosarcomas. This model will aid in understanding the disease
Area of Science:
- Cardiovascular Research
- Oncology
- Genetics
Background:
- Cardiac rhabdomyosarcomas are rare and poorly understood.
- Lack of established models hinders pathogenetic research.
Purpose of the Study:
- To create a transgenic mouse model for cardiac rhabdomyosarcoma formation.
- To facilitate systematic studies on disease pathogenesis.
Main Methods:
- Constructed a minigene using SM22alpha promoter and SV40 T antigen.
- Genotyped transgenic mice via polymerase chain reaction.
- Evaluated phenotypic expression using immunohistochemistry.
Main Results:
- Transgenic mice developed cardiac tumors by 8-12 weeks.
- Tumors showed increased cell density, enlarged nuclei, and higher DNA content.
- Histological analysis confirmed rhabdomyosarcoma criteria with specific protein markers.
Conclusions:
- This study presents the first genetically engineered mouse model for cardiac rhabdomyosarcoma.
- The model is crucial for elucidating disease pathogenesis.
- It offers a platform for testing novel therapeutic strategies.
